The UK authority that oversees the listing of companies on the London Stock Exchange is proposing to relax its rules so as to encourage biotechnology companies to raise money on the exchange. Currently, in order to list, a company must satisfy the Financial Services Authority (FSA; London) that it has, for example, two products in clinical trials, £5 million ($7.3 million) through collaborations, or has spent more that £20 million on R&D over the last 3 years and has IP to show for it. But now the FSA is going “to allow the admission of scientific research-based companies that do not meet the specific criteria absolutely, but nonetheless could achieve milestones appropriate to its business”—basically allowing companies to disclose information for investors to evaluate, rather than having to satisfy the FSA. Daniel Abrams, chair of the BioIndustry Association's (BIA; London) finance committee, welcomes the proposed changes, saying that “a credible biotechnology company can be created in six months, not necessarily over three years.” But he adds that, “I would not expect to see a large increase in the numbers of biotechnology companies listing.” After a consultation period closing on March 16, the FSA plans to implement any changes in the summer.